Biogen: No Sign Of Aducanumab Approval Catalyst In Current Market Valuation

Article feature image

Photo by selvanegra/iStock via Getty Images
Investment Thesis
June 7th is arguably the biggest day in the biotech and pharmaceutical calendar this year, since it is the day that the FDA – unless there is yet another twist in this saga – will announce its decision over whether to approve Aducanumab – Biogen’s (BIIB) and its partner Eisai’s (OTCPK:ESALF) once discarded, now resurrected, and widely discussed Alzheimer’s treatment.
To say that Aducanumab’s journey to this point has been controversial…

Click here to view the original article.

S&P/ASX 200 
7,039.00  24.80  0.35%  
ALL ORDINARIES 
7,270.20  30.80  0.43%  
Dow Jones Industrial Average 
34,382.13  360.73  1.06%  
S&P 500 
4,173.85  61.35  1.49%  
NASDAQ Composite 
13,429.98  304.98  2.32%  
NYSE COMPOSITE (DJ) 
16,415.36  233.76  1.44%  
FTSE 100 
7,043.61  80.28  1.15%  
DAX PERFORMANCE-INDEX 
15,416.64  216.94  1.43%  
Nikkei 225 
27,956.24  128.23  0.46%  
HANG SENG INDEX 
28,027.57  0.0000  0.00%